fibrodude84
Senior Member
- Messages
- 191
When will the 3rd reprint be available and what will be different?
Unfortunately the NHS don't accept the test Dr Myhill uses. (Mitochondrial assay). I would therefore advise people going down the investigatory route to 'prove' her theory as you will likely meet closed doors thoroughly welded shut.
We appear as patients, to be stuck in a strange time continuum, where a nothing ever changes politically, even if science based knowledge increases exponentially.
This means no matter how many books Dr Myhill writes, the general consensus is she is 'wrong' and on the 'fringe' of GP knowledge over ME and CFS.
Perhaps as patients, all we can do is read what 'ME friendly' doctors have to say and increase our own knowledge. Maybe from this we can be as well as possible whilst the professional opinion, is we don't need to go to such lengths?
It's such a sad situation but it's good to see at least a few doctors in the UK are not being hypnotized by the lure of psychobehavioural theories of CFS explaining chronic neuroimmune illness.
It's certainly ridiculous that they can't accept a theory for which exists verifiable evidence without even bothering to explain why they reject it! or do they give any explanation of why they reject so many theories based on scientific method? I always asked myself that... is it just that they don't care about hiding that all that matters to them is to benefit the psychologists that bribe them? perhaps you can enlighten me on this, Research 1st, can you?
She has written three papers, two of which are described as 'audits', which means that there was no prospective experimental planning and the findings can only be taken as decriptive.
... this raises an issue that we've discussed on another thread - that of clinicians doing audits of their therapies when RCTs aren't possible for them (whether because it's outside their expertise or because patients want treatment and aren't willing to be randomised).
I agree that retrospective audits have their weaknesses but I think that if we reject clinical audits wholesale we might miss some potentially useful therapies. ...in the meantime, relatively low-risk, inexpensive, over-the-counter treatments with even slight-to-moderate effects would be great. Those treatments with slight-to-moderate effects are the sort that need an audit to catch them (rather than being so obvious, like rituximab, that you can go almost straight to an RCT).
I'd like to see a sort of template for our clinicians about how to do a prospective study whose results would be taken seriously. Standard diagnostic inclusion criteria, preplanned stopping points, outcome measures including actimeter data, that sort of thing.
But what business do clinicians have handing out treatments that have not been through reliable trials, Sasha?
Trials are never outside clinicians' expertise since trial design is a standard part of all medical training.
Perhaps patients would be readier to be randomised if the clinician was honest and said they had no idea if the treatment worked yet!
This handing out of untested treatments in ME is something that does not occur in other specialities.
I agree that audits can be useful when you seem to see a pattern, perhaps of remission, in a context that you had not thought about in advance and wanted to firm up that there really was a pattern. But when you first use a therapy there is no reason to do an 'audit' rather than a prospective trial. It is just laziness.
And you've got it back to front about major and moderate effects. It is the drugs that have mild to moderate effects that need RCTs - like aspirin to prevent stroke for instance. Audits tell you nothing. When drugs obviously work the stringency you need is much less.
The general principles are taught to all medical students and registrars. They should know. But there are no hard and fast rules for any particular trial design. There are all sorts of ways of doing trials as long as the structure satisfies the basic common sense principles to do with blinding when needed, controls of one sort or another, outcome measures suited to the particular question.
I agree that audits can be useful when you seem to see a pattern, perhaps of remission, in a context that you had not thought about in advance and wanted to firm up that there really was a pattern. But when you first use a therapy there is no reason to do an 'audit' rather than a prospective trial. It is just laziness. And you've got it back to front about major and moderate effects. It is the drugs that have mild to moderate effects that need RCTs - like aspirin to prevent stroke for instance. Audits tell you nothing. When drugs obviously work the stringency you need is much less.
But what business do clinicians have handing out treatments that have not been through reliable trials, Sasha?
I think first and foremost Dr Myhill is just a doctor who has conducted some research with limited type trials and found them effective in some of her patients. Whether this can be classified as dangerous is a mute point I think.
However, I dont think the medical profession are in a position to say they only hand out drugs after 'gold standard' research and FDA trials which I think is what you may be implying
The Medical profession(at least in the US),appears to hand out quite strong drugs with limited scientific evidence in 'off label' usage.
...the link with allergies, microorganisms and aspects of the Western lifestyle.
thank you for your explanation Jonathan, It was very useful...I think it is good not to jump to conclusions about people's motives without a little careful thought, lauluce. My only motive here is that I find ME a worthwhile problem to try to understand in my retirement. I have no time for 'cognitive' approaches. I am helping to set up an immunological study but it does not matter to me personally whether or not it gives a positive or negative answer. I am just hoping we can find something reliably effective for patients' sake.
And I do not see any substantive science in relation to Dr Myhill's work. I am not sure that I can even work out what the theory is. She has written three papers, two of which are described as 'audits', which means that there was no prospective experimental planning and the findings can only be taken as decriptive. The third paper deals with a series of tests on neutrophil respiration and I find it very hard to work out what it means. I would not be surprised if neutrophils behaved differently in PWME simply because neutrophil traffic is likely to be dependent on exercise.
So I see nothing ridiculous in not accepting this theory, if there is one, - we do not even have independent researcher verification, which is the gold standard of all science. No sensible scientist is going to take this seriously at this stage.
The problem is that she cannot possibly know whether they work or not. Demonstrating drug efficacy against background of both patient and doctor expectations is pretty much impossible except for dramatic effects. Doctors have traditionally assumed that they can judge whether their treatments work but we now know that people will go on giving and receiving completely ineffective treatments for centuries. Samuel Hahnemann wrote a pharmacopeia for treatments for almost all known diseases in around 1800 and people are still using them today despite them having nothing in them. He cannot possibly have known whether they were effective anyway. It would have taken him a lifetime to get minimal evidence on all those empty tablets in all those diseases.
We start with the problem that doctors have been hopelessly overoptimistic about their ability to discover effective treatments. These doctors could be considered 'well-meaning' in the past but now we know the reality I don't think 'well-meaing' will do any more. And many of them are taking in large amounts of cash from people they are treating. I do not consider selling unproven services to people at high cost 'well-meaning'.
I think there is a major difference between medical services in the US and the UK . The great majority of medical care in the UK is NHS based and in recent times open label treatment has died down to a minimum. In the US where commercial interest dominates care policy I suspect things have not changed so much.
There are specific situations where off label treatment makes sense. For rare conditions such as dermatomyositis it may not be possible to gather enough patients to do a trial. When such conditions are life threatening it obviously makes sense to treat off label. Intravenous immunoglobulin has been used in a wide range of rare conditions as a last resort and still is. But ME is a common condition. Clinicians see hundreds of patients a year. And doing controlled trials of pills is not expensive. It might mean you are busy at the weekend transferring data from clinic notes to your trial folders and doing some statistics but it would be perfectly possible for a private practitioner to do this at more or less no cost. If you cannot get dummy pills you can compare two treatments - which is a perfectly valid way, although less powerful. I honestly do not think there is an excuse here. I have been through all this myself and done the copying at the weekend. For the first rituximab trial I bought the drug with my bank account - and it wasn't cheap!
I do have a problem with statements like :
“It's official - it's mitochondria, not hypochondria!"
While it's an attractive theory, not least because it seems to have some face validity, from what I've seen of the Myhill/Booth etc study, which is presumably what this claim rests on, their research approach cannot in any sense constitute 'proof'.
If I recall correctly, they used a novel test of mitochondrial function to show dysfunction in a ME/CFS population where mitochondrial dysfunction remains a theory. It may have made more sense if they had shown mito dysfunction in ME/CS using an established test or to have shown that their novel test performed better in known mitochondrial disorders. But the way they went about it just heaps one unknown on top of another. Bizarre!
ME/CFS patients may have shown different results to controls (if they used controls - I can't recall) but there's no reliable way to interpret this.
I'm happy to be corrected on the details of this.
That statement gives PWME hope after many years of being rejected by GP's, Consultants, Employers and even some family members. Therefore the Mitochondrial Function Profile test is the first definitive proof that it's not a psychological disorder.
My mito test showed insufficient energy delivery 13 months ago, I am much fitter now and will be doing the mito test in time to back up the way I feel.